Literature DB >> 8832651

Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease.

P Rezaie1, N J Cairns, A Chadwick, P L Lantos.   

Abstract

Lewy bodies (LBs)are found throughout the brain stem, limbic and neocortical areas in Parkinson's disease. Lewy bodies are also associated in these areas with dementia and the substrate of 'dementia with Lewy bodies' is thought to include Lewy body pathology in limbic and neocortical areas with or without Alzheimer-type changes. In order to determine whether dementia with Lewy bodies is characterised primarily by cortical or limbic LB pathology, we have measured the density of Lewy bodies, neuritic plaques and neurofibrillary tangles in 12 neocortical, limbic and brain stem sites in 10 patients who were pathologically diagnosed with diffuse Lewy body disease (DLBD) (64.7 +/- 2.7 years). The mean LB density in limbic areas (3.00 +/- 0.61/mm2) was significantly greater than that of neocortical areas (1.13 +/- 0.22/mm2, P < 0.001). The greatest density of LBs was found in the amygdala (4.1 +/- 0.7/mm2) and the lowest in the occipital cortex (0.3 +/- 0.1/mm2). In limbic areas, LB formation positively correlated with neuritic plaque formation (r = 0.51, P < 0.01) but not with neurofibrillary tangle densities. These data indicate that dementia with Lewy bodies is characterised primarily by limbic, and secondly by neocortical, LB pathology. It remains to be determined why limbic areas are selectively vulnerable to LB pathology in dementia with Lewy bodies.

Entities:  

Mesh:

Year:  1996        PMID: 8832651     DOI: 10.1016/0304-3940(96)12775-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors:  Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-04-25       Impact factor: 10.338

2.  Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease.

Authors:  Micaela Mitolo; Joanne M Hamilton; Kelly M Landy; Lawrence A Hansen; Douglas Galasko; Francesca Pazzaglia; David P Salmon
Journal:  J Int Neuropsychol Soc       Date:  2016-05-25       Impact factor: 2.892

Review 3.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

4.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

5.  Seizures in corticobasal degeneration: a case report.

Authors:  Vanja C Douglas; Stephen J DeArmond; Michael J Aminoff; Bruce L Miller; Gil D Rabinovici
Journal:  Neurocase       Date:  2009-06-18       Impact factor: 0.881

Review 6.  Dementia-related psychosis and the potential role for pimavanserin.

Authors:  Jeffery L Cummings; D P Devanand; Stephen M Stahl
Journal:  CNS Spectr       Date:  2020-08-19       Impact factor: 3.790

Review 7.  Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson's Disease.

Authors:  Sean J Miller; Cameron E Campbell; Helen A Jimenez-Corea; Guan-Hui Wu; Robert Logan
Journal:  Front Neurosci       Date:  2022-04-19       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.